Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sound waves plus immunotherapy: a new attack on breast cancer before surgery

NCT ID NCT06964906

Recruiting now Disease control Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This trial investigates whether combining high-intensity focused ultrasound (HIFU) with the immunotherapy drug toripalimab and standard chemotherapy can improve outcomes for people with ER+/HER2- breast cancer before they undergo surgery. The study enrolls women aged 18-75 with invasive, non-metastatic breast cancer. The goal is to see if this approach leads to a complete disappearance of cancer in the breast and lymph nodes at the time of surgery.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of high-intensity focused ultrasound (HIFU), toripalimab, and chemotherapy drugs (nab-paclitaxel, epirubicin, cyclophosphamide)
What this could lead to
If successful, this combination could become a new pre-surgery treatment option for ER+/HER2- breast cancer, potentially increasing the chance of eliminating all cancer before surgery.
What could go wrong
This is a small, early-phase study with only 30 participants, so results may not apply to all patients. The combination may cause significant side effects and may not improve outcomes compared to standard therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ER+/HER2- BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm estrogen-receptor positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ER+/HER2- BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • 2nd Affiliated Hospital, School of Medicine, Zhejiang University

    RECRUITING

    Hangzhou, Zhejiang, 310000, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.